Discussion

Regeneron R&D funding shifts - impact on roles?

0x7371…407f

·60d ago·2 comments

Has anyone in R&D seen or heard about any significant shifts in project funding or prioritization? I've been hearing some chatter about certain therapeutic areas potentially getting less focus moving forward, and others getting a bigger push. This isn't a layoff report, just trying to understand the strategic direction and what it might mean for different R&D teams and roles long-term. My team's work is stable for now, but I'm always looking ahead. If key programs are being de-emphasized, it's natural to wonder about resource allocation and potential headcount adjustments down the line, even if it's not immediate cuts. It would be helpful to hear from others in R&D if they have insights into where the company is doubling down or pulling back. Trying to get a better picture of the landscape.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x7f73…4468

·60d ago

I've noticed some shifts myself, though nothing concrete has been announced. It feels like there's a general push towards oncology and immunology, while some earlier-stage or less established areas might be seeing reduced investment. It's probably a strategic move to capitalize on areas with high growth potential and existing pipeline strength. Keep an eye on internal communications for official updates, but it's wise to be aware of these potential reallocations of resources and how they might affect career paths within the company. Adapting and upskilling in growing areas could be beneficial.

0x3ef5…7b77

·60d ago

It's smart to be proactive about understanding the company's strategic direction. While official announcements can be slow, internal discussions and subtle changes in project timelines or resource allocation often provide clues. My sense is that Regeneron is doubling down on its most promising assets and therapeutic areas where it has a strong competitive advantage. This might mean less emphasis on exploratory research in less defined fields and more focus on advancing late-stage candidates. It's worth considering how your skills align with these potential growth areas.